Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin:: A report of the German Hodgkin's lymphoma Study Group

被引:40
作者
Bredenfeld, H
Franklin, J
Nogova, L
Jesting, A
Fries, S
Mailänder, V
Oertel, J
Diehl, V
Engert, A
机构
[1] Univ Hosp Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
[2] Univ Hosp Rudolf Virchow, Berlin, Germany
[3] Univ Hosp Benjamin Franklin, Berlin, Germany
[4] Univ Hosp Nuremberg, Nurnberg, Germany
关键词
D O I
10.1200/JCO.2004.09.114
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To investigate a new effective, nonleukemogenic polychemotherapy regimen, BAGCOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, gemcitabine) in a phase I/II dose-escalation study in patients with advanced-stage Hodgkin's disease (HD). Patients and Methods Patients in clinical stages IIB with risk factors III and IV were enrolled in this nonrandomized, multicenter trial aimed at defining the maximum-tolerated dose of gemcitabine within a modified escalated BEACOPP regimen. Gemcitabine was given at a starting dose of 800 mg/m(2) on days 1 and 4 of each cycle. Results Twenty-seven patients (eight female, 19 male) were enrolled with a median age of 33 years (range, 19 to 65 years). Due to a higher than expected hematotoxicity, the day-4 application of gemcitabine was omitted after 14 patients were included and 59 cycles were given. A total of eight patients developed lung toxicity, mainly pneumonitis (six of eight), which led to the termination of the study. With a median follow-up of 27 months, 25 patients are in continuing complete remission. Conclusion The substitution of etoposide by gemcitabine in the escalated BEACOPP schema is not feasible and leads to severe pulmonary toxicity. This toxicity is probably related to the concomittant application of gemcitabine and bleomycin. (C) 2004 by American Society of Clinical Oncology.
引用
收藏
页码:2424 / 2429
页数:6
相关论文
共 37 条
[1]   Gemcitabine - a safety review [J].
Aapro, MS ;
Martin, C ;
Hatty, S .
ANTI-CANCER DRUGS, 1998, 9 (03) :191-201
[2]   Drug-induced respiratory disorders: Incidence, prevention and management [J].
Ben-Noun, L .
DRUG SAFETY, 2000, 23 (02) :143-164
[3]  
BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO
[4]  
2-7
[5]  
Bredenfeld H, 2001, BLOOD, V98, p338A
[6]  
DEVITA VT, 1993, NEW ENGL J MED, V328, P560
[7]   BEACOPP:: A new regimen for advanced Hodgkin's disease [J].
Diehl, V ;
Franklin, J ;
Hasenclever, D ;
Tesch, H ;
Pfreundschuh, M ;
Lathan, B ;
Paulus, U ;
Sieber, M ;
Rüffer, JU ;
Sextro, M ;
Engert, A ;
Wolf, J ;
Hermann, R ;
Holmer, L ;
Stappert-Jahn, U ;
Winnerlein-Trump, E ;
Wulf, G ;
Krause, S ;
Glunz, A ;
von Kalle, K ;
Bischoff, H ;
Haedicke, C ;
Dühmke, E ;
Georgii, A ;
Loeffler, M .
ANNALS OF ONCOLOGY, 1998, 9 :67-71
[8]   Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J].
Diehl, V ;
Franklin, J ;
Pfreundschuh, M ;
Lathan, B ;
Paulus, U ;
Hasenclever, D ;
Tesch, H ;
Herrmann, R ;
Dörken, B ;
Müller-Hermelink, H ;
Dühmke, E ;
Loeffler, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2386-2395
[9]   DOSE-ESCALATION STUDY FOR THE TREATMENT OF HODGKINS-DISEASE [J].
DIEHL, V .
ANNALS OF HEMATOLOGY, 1993, 66 (03) :139-140
[10]   Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease [J].
Friedberg, JW ;
Neuberg, D ;
Kim, H ;
Miyata, S ;
McCauley, M ;
Fisher, DC ;
Takvorian, T ;
Canellos, GP .
CANCER, 2003, 98 (05) :978-982